The mixed analyst ratings for Chemours indicate that there is no clear consensus on the stock's short-term direction. The average 12-month price target has increased by 2.96%, which may have a positive impact on the stock price, but the presence of both bullish and bearish ratings suggests that the market is divided on the company's prospects. As a result, the short-term impact on the stock price is neutral.